ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
22. Oktober 2019 02:45 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability...